Cancer clinical trials in the region Nouvelle-Aquitaine

397 currently recruiting clinical trials
Region Nouvelle-Aquitaine
Phase 3 Colon cancer Rectal cancer # NCT06642844
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Centre Hospitalier Universitaire de Tours
Phase 2 / Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT07129993 #2024-516906-47-00
Required histologic types
Invasive bladder cancer Upper excretory tract cancer Urethral cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
15 recruiting sites
Daiichi Sankyo
Phase 2 / Phase 3 Endometrial cancer #NCT03651206 #2024-516782-36-00
Required histologic sub types
Carcinosarcoma
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive Immunotherapy Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Targeted therapy
16 recruiting sites
ARCAGY/ GINECO GROUP
Phase 2 / Phase 3 Multiple myeloma #NCT07095452 #2025-520897-21-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required IMWG cytogenetic prognoses
High risk
15 recruiting sites
Abbvie
Phase 2 / Phase 3 Lung cancer #NCT07063745 #2025-521511-40-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required genetic anomalies
MTAP
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Targeted therapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
13 recruiting sites
Bristol-Myers Squibb
Phase 2 / Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06161025 #2023-507914-28-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC) Endometrioid carcinoma
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required platino resistance
Recurrence within 6 months after platinum-based tr...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Daiichi Sankyo
Phase 2 / Phase 3 Head and neck cancer #NCT06788990 #2024-519654-37-00
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required HPV statuses
HPV Negative
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
12 recruiting sites
Bicara Therapeutics
Phase 2 / Phase 3 Head and neck cancer #NCT04534205 #2020-001400-41
Required histologic types
Oral cavity Oropharynx Hypopharynx Larynx Salivary glands Nasal cavities and sinuses
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required P16 statuses
P16 Positive
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
6 recruiting sites
BioNTech SE
Phase 2 / Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT07106762 #2025-522400-24-00
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy Antibody Drug Conjugates (ADC)
10 recruiting sites
Bristol-Myers Squibb
Phase 2 / Phase 3 Lung cancer #NCT05255302 #2024-515945-40-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK EGFR HER2 NTRK-1/2/3 RET ROS-1 Other mutation
Excluded previous treatments at localized stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Targeted therapy
12 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique